Evidence map›Paper›PMID 37395935›Full record

ArticleJournal of cancer survivorship : research and practice2024

Quality of life assessment in testicular non-seminomatous germ cell tumour survivors.

Neha Pathak, Abhishek Raj, Akhil P Santhosh, Sudhir Kumar, K P Haresh, Prabhjot Singh, Brusabhanu Nayak, Shamim Ahmed Shamim, Amlesh Seth, Mukurdipi Ray and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Neha PathakDepartment of Medical Oncology, Dr B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India.
Abhishek RajDepartment of Medical Oncology, Dr B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India.
Akhil P SanthoshDepartment of Medical Oncology, Dr B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India.
Sudhir KumarDepartment of Medical Oncology, Dr B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India.
K P HareshDepartment of Radiation Oncology, Dr B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India.
Prabhjot SinghDepartment of Urology, All India Institute of Medical Sciences, New Delhi, India.
Brusabhanu NayakDepartment of Urology, All India Institute of Medical Sciences, New Delhi, India.
Shamim Ahmed ShamimDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Amlesh SethDepartment of Urology, All India Institute of Medical Sciences, New Delhi, India.
Mukurdipi RayDepartment of Surgical Oncology, Dr B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India.
Seema KaushalDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Ranjit Kumar SahooDepartment of Medical Oncology, Dr B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India. drranjitmd@gmail.com.
Atul BatraDepartment of Medical Oncology, Dr B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, India. batraatul85@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with Germ cell tumours (GCT) are at risk of long-term toxicities due to multimodality therapy. It is debatable whether there is an impact on the quality of life(QoL) of GCT survivors.

methodsA case-control study was conducted at a tertiary care centre in India, using the EORTC QLQ C30 questionnaire, to compare the QoL between GCT survivors(disease free > 2 years) and healthy matched controls. A multivariate regression model was used to identify factors affecting QoL.

resultsA total of 55 cases and 100 controls were recruited. Cases had a median age of 32 years (interquartile range, IQR 28-40 years), ECOG PS of 0-1(75%), advanced stage III (58%), chemotherapy (94%) and 66% were > 5 years from diagnosis. The median age of controls: 35 years (IQR 28-43 years). A statistically significant difference was seen for emotional (85.8 ± 14.2 vs 91.7 ± 10.4, p 0.005), social(83.0 ± 22.0 vs 95.2 ± 9.6, p < 0.001) and global scales (80.4 ± 21.1 vs 91.3 ± 9.7, p < 0.001). Cases had more nausea and vomiting(3.3 ± 7.4 vs 1.0 ± 3.9, p 0.015), pain(13.9 ± 13.9 vs 4.8 ± 9.8, p < 0.001), dyspnea(7.9 + 14.3 vs 2.7 ± 9.1, p 0.007), and appetite loss(6.7 ± 14.9 vs 1.9 ± 7.9, p 0.016) and greater financial toxicity(31.5 ± 32.3 vs 9.0 ± 16.3, p < 0.001). Adjusting for age, performance status, BMI, stage, chemotherapy, RPLND, recurrent disease, and time since diagnosis, no predictive variables were significant.

conclusionThere is a detrimental impact of history of GCT in long term survivors of GCT.

Indexed as

Cancer SurvivorsNeoplasms, Germ Cell and EmbryonalQuality of LifeTesticular NeoplasmsAdultCase-Control StudiesHumansMaleSurveys and QuestionnairesGerm cell tumourQuality of lifeSurvivorshipTesticular cancer

Identifiers

PMID37395935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.